DAX+0,49 % EUR/USD+0,18 % Gold+0,12 % Öl (Brent)+1,96 %

Pharming Group -- der absolute Traum für jeden Anleger ! Kursziel 1,50 € ! (Seite 4)


ISIN: NL0010391025 | WKN: A1H65A | Symbol: PHGN
0,835
$
24.05.19
Nasdaq OTC
-1,72 %
-0,015 USD

Begriffe und/oder Benutzer

 

Antwort auf Beitrag Nr.: 57.359.531 von SV34 am 22.03.18 19:29:22Ich spreche von dem geschätzten KGV für 18 und 19
Spannend wird es doch erst bald...
http://www.boerse-online.de/nachrichten/aktien/Pharming-Group-Aktie-Warum-Anleger-jetzt-einsteigen-sollten-1018699031
https://www.pharming.com/release-annual-report-2017/

https://www.pharming.com/downloads/Annual_Report_2017.pdf

I look forward with confidence to continuing the upward story of Pharming in 2018, with salesincreasing
further, a new exciting pipeline and new opportunities for enhanced shareholder value.
Leiden, 28 March 2018
Sijmen de Vries
Chief Executive Officer and Chairman of the Board of Management
Antwort auf Beitrag Nr.: 57.734.029 von berhem am 10.05.18 14:15:32Widerstand bei 1,50 €. Da liegen Stück 10.000 zum Verkauf von mir. Habe meinen Bestand letzte Woche halbiert.
Das gleiche Spiel wie beim letzten Quartalsbericht.
Die Zahlen sind gut , aber die Erwartungen waren höher.
Der Kurs wird sich wieder erholen.
Die Pipeline und die Perspektiven in diesem Jahr sind gut.
Am 21.06. Markets Briefing und dann am 21.09. FDA Entscheid.
Bin sehr positiv und nutze den Kursrücksetzer zum Nachkauf.
http://nebula.wsimg.com/1f588297beb29ae74461bd3a9348c3bf?AccessKeyId=F1B3D293B900048B2E3E&disposition=0&alloworigin=1




ProQR Therapeutics (PRQR): Initiating Report 26 April
ProQR Therapeutics is an innovative biopharma company that is developing RNA-based therapeutics for the treatment of severe genetic disorders such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. The company’s growing pipeline is based on its proprietary technology platform of RNA technologies. Its lead program is eluforsen (formerly QR-010), which is currently in Phase IB for cystic fibrosis. Eluforsen is expected to advance into a phase II study in 2018. We believe the company will aim for a partnership with big pharma in order to focus on its programs in retinal dystrophy. QR-110 is a therapy designed to address the underlying cause of Leber’s congenital amaurosis (LCA) 10. A Phase 1b/2 trial for QR-110 was initiated in 2017Q4, and we expect initial results in 2018. Using our valuation model and taking into account a potential partnership with eluforsen and future revenues of QR-110, the company’s current total value should be USD 350-400 million, or USD 11.00-12.50 per share.


Pharming (PHARM.AS): Research Note 17 May
Pharming Group published its 2018Q1 figures which were in line with our expectations. For the first time, the company reached profitability with net profit of EUR 3.3 million. We think it is positive that the company managed to sustain and even slightly improve sales of RUCONEST® compared to the already strong fourth quarter of 2017. The company expects continued growth in revenues, mainly driven by the US sales of RUCONEST®. Pharming also believes it will achieve positive net results throughout the course of the year. Based on our NPV based valuation, we believe that Pharming is still substantially undervalued at the current share price of EUR 1.38. We have increased our valuation for the company and estimate that the company’s current total value should increase from EUR 1.1 billion to EUR 1,6 million, which translates, based on an expected number of issued shares of approximately 657 million, into EUR 2.40 per share.


Beitrag zu dieser Diskussion schreiben